Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Top Cited Papers
Open Access
- 18 March 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (12), 1189-1199
- https://doi.org/10.1056/nejmoa030897
Abstract
Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years.Keywords
This publication has 44 references indexed in Scilit:
- Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive AgentsJournal of Clinical Endocrinology & Metabolism, 2002
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women:: The EPIDOS studyBone, 2000
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityJournal of Clinical Endocrinology & Metabolism, 2000
- Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosisArthritis & Rheumatism, 1999
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1998
- Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of AgeNew England Journal of Medicine, 1998
- Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosisThe American Journal of Medicine, 1996
- Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisBone, 1996
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisThe American Journal of Medicine, 1993